Eine Zirkulierende Nicht-Kodierende Rna zur Vorhersage der Sterblichkeit der Patienten mit Akutem Nierenversagen

Details

Veröffentlichungs-Nr.

EP2985351

Aktenzeichen

EP14181091

Anmeldetag

14. August 2014

Veröffentlichung

4. Oktober 2017

Erteilung

4. Oktober 2017

Rechtsraum

EP

IPC

C12Q1/68

Abstract

The present invention relates to a a method for predicting mortality of a test patient with acute kidney injury comprising (a) detecting the expression level of the non-coding RNA (ncRNA) of SEQ ID NO: 1 in a sample obtained from said test patient with acute kidney injury, (b) comparing said expression level of the ncRNA with the expression level of this ncRNA in a sample obtained from control patients with acute kidney injury or with a predetermined standard expression level of this ncRNA which was obtained on the basis of a sample from control patients with acute kidney injury, wherein the control patients were alive at least about 4 weeks after diagnosis of the acute kidney injury, and a greater than 1.5-fold overexpression of the ncRNA in the test patient's sample as compared to the control patient's sample or as compared to the predetermined standard is indicative of an enhanced likelihood for future death of the test patient due to renal failure; and/or (b') comparing said expression level of the ncRNA with the expression level of this ncRNA in a sample obtained from control patients with acute kidney injury or with a predetermined standard expression level of this ncRNA which was obtained on the basis of a sample from control patients with acute kidney injury, wherein the control patients died from renal failure within about 4 weeks after diagnosis of acute kidney injury, and a greater than 1.5-fold underexpression of at the ncRNA in the test patient's sample as compared to the control patient's sample or as compared to the predetermined standard is indicative of an enhanced likelihood for the long term survival of the test patient; and/or (b") comparing said expression level of the ncRNA with the expression level of the ncRNA in a sample obtained from a healthy subject or with a predetermined standard expression level of this ncRNA which was obtained on the basis of at least one sample from a healthy subject, wherein a greater than 5-fold overexpression of the ncRNA in the test patient's sample as compared to the healthy sample or as compared to the predetermined standard is indicative of an enhanced likelihood for future death of the test patient due to renal failure.

Anmelder

Firma

Medizinische Hochschule Hannover

Land

🇩🇪 Deutschland

Fachgebiete